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Introduction
Pulmonary surfactant reduces the surface tension at the
air–liquid interface throughout the lung by forming a lining
layer between the aqueous airway liquid and the inspired
air. The major component of surfactant, dipalmitoyl-
phosphatidylcholine (DPPC), is an amphiphatic phospho-
lipid. Its polar head region is associated with the aqueous
hypophase lining the airways whereas the hydrophobic
fatty acid chains face the luminal air. Surfactant-specific
proteins facilitate the arrangement of phospholipids in the
lining layer, thereby optimizing surface-tension-reducing
capacity. This important function prevents alveolar and
airway collapse at end-expiration and thus allows cyclic
ventilation of the lungs. After the discovery of the basic
functional principle of pulmonary surfactant more than 70
years ago, the pulmonary surfactant system has been
intensively investigated and more than 9000 publications
have revealed numerous aspects of surfactant synthesis,
secretion, metabolism and various functions in the alveolar
compartment.
The pathogenetic relevance of surfactant was initially rec-
ognized in infant respiratory distress syndrome as a quan-
titative surfactant deficiency [1], but today biochemical
and biophysical surfactant abnormalities are reported in
various lung diseases, such as acute respiratory distress
syndrome, pneumonia, and cardiogenic lung edema [2].
The precise composition of surfactant in health and
disease is known down to the genetic code of its specific
proteins. While surfactant was initially thought to be a key
player in the biophysical behavior of the lung, today its
immunomodulatory properties make surfactant a fascinat-
ing compound in innate and adaptive immunity of the lung.
Surfactant proteins act as a first-line defense against
invading microorganisms. Moreover, they possess binding
capacity for aeroallergens, highlighting the possible role of
the pulmonary surfactant system in allergic diseases such
as asthma.
The possible involvement of pulmonary surfactant in the
pathophysiology of respiratory diseases with a predomi-
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nant disturbance in the conducting airways, such as
asthma, has only recently been addressed [3]. Asthma is
characterized by chronic inflammation of the airways with
eosinophils and T helper lymphocytes associated with
bronchial hyper-responsiveness, which causes a
reversible form of airway obstruction after inhalation of a
variety of stimuli. Airway obstruction with increased airway
resistance in asthma, which is commonly thought to be
caused by smooth muscle constriction, mucosal edema
and secretion of fluid into the airway lumen, may partly be
due to a poor function of pulmonary surfactant. In the past
decade, direct and indirect evidence has emerged for sur-
factant as a factor in the regulation of airway calibers and
a modulator of allergic inflammation. The following sec-
tions review the potential role of surfactant in asthma.
Airway surfactant
Morphology
The majority of surfactant is synthesized and secreted by
alveolar type II cells. During expiration, alveolar surfactant
becomes extruded into the adjacent conducting airways.
Electron microscopy has revealed that surfactant material
forming monolayers and multilayers can be found at the
air–liquid interface of the airway lumen. In addition, multi-
lamellar vesicles and lattice-like tubular myelin can be
found within the hypophase of the epithelial lining fluid
covering the airways [4]. Immunohistochemistry and in
situ hybridization studies demonstrated that surfactant
protein and mRNA expression are not restricted to alveolar
type II cells. Whitsett and coworkers [5] have shown that
during lung development, the hydrophobic surfactant
protein (SP)-B and SP-C mRNAs are first expressed in
bronchi and bronchioles. Expression in epithelial cells of
the bronchiolo-alveolar portals and in type II cells
increased with gestational age [5]. In the fetal and adult
human lung, SP-B and SP-C are expressed primarily in
distal conducting and terminal airway epithelium [5]. Sur-
factant-protein synthesis has been shown in Clara cells
[6,7] and SP-A and SP-D were also found in more proxi-
mal parts of the respiratory tract [8–10]. In addition to the
spatial distribution of surfactant proteins, local synthesis
and release of phospholipids in tracheal epithelial cells
have been demonstrated [11]. Clara cells do not,
however, secrete or synthesize lamellar bodies or DPPC.
To conclude, local synthesis of surfactant components in
the airways might indicate the possibility of adaptation and
regulation of the airway surfactant system.
Composition
Studying the composition of airway surfactant still has
major limitations, as there is no method for selective sam-
pling of surfactant from the conducting airways. It has
been demonstrated that airway secretions from tracheal
aspirates contain significant amounts of surfactant with a
phospholipid composition similar to alveolar surfactant
[12,13]. In contrast, the concentrations of surfactant pro-
teins have been found to be decreased in tracheal aspi-
rates from porcine lungs [12]. In patients with asthma, the
percentage of DPPC decreased in sputum but not in
bronchoalveolar lavage fluid (BALF), while SP-A levels
were found to be unchanged [13]. Interestingly, the per-
centage of DPPC in sputum correlated to the lung func-
tion variable FEV1 (forced expiratory volume in 1 s). Van
de Graaf et al. [14] reported that BALF levels of SP-A
were decreased in patients with asthma. Accordingly, it
has been reported that mite-allergen-induced airway
inflammation leads to decreased levels of SP-A and SP-D
in BALF from sensitized mice [15]. In contrast, Cheng
and co-workers [16] found increased levels of SP-A and
SP-D in bronchial and alveolar lavages in mild, stable
asthmatics compared with controls. The discrepancy of
these findings might be due to different time points and
methods of sampling of the lavage fluids, and requires
further clarification.
Biophysical aspects
Airway surfactant reduces surface tension at the air–liquid
interface of conducting airways. This decreases the ten-
dency of airway liquid to form bridges in the more narrow
airway lumen (film collapse). In addition, a low surface
tension minimizes the amount of negative pressure in the
airway wall and its adjacent liquid layer, which in turn
decreases the tendency for airway wall (‘compliant’) col-
lapse. According to the law of LaPlace that applies to
cylinders (P = γ/r, where p is transmural pressure, γ is
surface tension, and r is airway radius), it becomes
obvious that the smaller the airways become, the higher
the pressure would rise if surface-active material lowering
the value of γ were absent. Surface tension in the con-
ducting airways has been shown to be in the range
25–30 mN/m [12,17]. This causes transmural pressures
of less than 1 cmH2O whereby the patency of airways is
maintained. By preventing both film collapse and compli-
ant collapse, airway surfactant secures airway architecture
and its openness.
Capillary surfactometer
A simple method to estimate surfactant function, as it
applies to the cylindrical surface of a narrow conducting
airway, is the capillary surfactometer. This instrument sim-
ulates the morphology and function of a terminal conduct-
ing airway with a glass capillary that in a short section is
particularly narrow with an inner diameter of 0.2 mm
[18–20]. It utilizes a very small volume (0.5 µl) of surfac-
tant. By raising the pressure, the liquid is extruded from
the narrow section. Pressure is zero if the capillary is open
for free airflow, but there is an increase in pressure when
the liquid returns to block the narrow section. Well func-
tioning pulmonary surfactant will keep the capillary open
100%, showing an excellent ability to maintain airway
patency, whereas when surfactant functions very poorly,
the value of ‘open in %’ will be zero.Page 3 of 8
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Airway models
Liu  et al. [18] found that surfactant-containing fluid
allowed a free airflow through the tube whereas saline led
to spontaneous refilling of the capillary. The ability of sur-
factant to maintain free airflow was lost with the addition
of albumin or fibrinogen (two potent surfactant inhibitors).
In a recent study, we demonstrated that surfactant dys-
function by proteins was further disturbed by cooling [21].
This may explain the finding of increased airway resistance
in patients with exercise-induced asthma where airway
surfactant with sufficient surface activity becomes seri-
ously inactivated due to cooling during exercise with
hyperventilation of cold air. The principal findings of sur-
factant function and dysfunction in the rigid airway model
using the capillary surfactometer have been confirmed
using an elegant approach to study conducting airway
function in excised isolated rat lungs [22].
Other functions
Surfactant also contributes to the regulation of airway fluid
balance, improves bronchial clearance and sets up a
barrier to inhaled agents. Firstly, the high surface pressure
(low surface tension) of surfactant counteracts fluid influx
into the airway lumen. Loss of surface activity would result
in additional inward forces that cause fluid accumulation in
the airway lumen. The influence of surfactant on airway
liquid balance also includes prevention of desiccation.
Secondly, surfactant improves bronchial clearance by opti-
mizing transport of particles and bacteria from the periph-
eral to the more central airways. Moreover, surfactant has
been shown to enhance mucociliary clearance [23], partly
by increasing ciliary beat frequency [24]. Thirdly, several
studies have suggested that surfactant sets up a barrier to
the diffusion of inhaled agents, including bacteria, aller-
gens and drugs [25,26]. For example, depletion of the sur-
factant layer by lung lavage leads to augmented
responses to drugs and allergens [27,28]. Interestingly,
exogenous surfactant treatment lessens the airway
response to inhaled, but not systemically given, bron-
choconstrictor stimuli in rats, suggesting an airway barrier
to drug diffusion [29]. In addition, it has recently been
shown that treatment of rats with exogenous phospho-
lipids suppresses the neural activity of bronchial irritant
receptors [30]. This may support the view of a possible
link between airway hyper-responsiveness and airway sur-
factant balance.
Immunological aspects
Besides the important biophysical properties of pul-
monary surfactant, its role in immunomodulation has
attracted increasing interest in asthma. The hydrophilic
surfactant proteins SP-A and SP-D are important compo-
nents of the innate immune response. They are members
of the collectins, a family of oligomeric molecules contain-
ing a collagen-like domain and a calcium-dependent
lectin domain, known as a carbohydrate recognition
domain. The ability of lung collectins to regulate immune
cells has been shown to be affected by the presence of
lipids [31]. In asthma, the important immune cells in the
allergic inflammatory response are dendritic cells, T-
helper lymphocytes, IgE-producing B lymphocytes
(plasma cells), mast cells and eosinophils. Of course,
airway inflammation in asthma is a more complex scenario
that also includes epithelial cells, smooth muscle cells
and parenchymal cells; however, available data on the
effect of surfactant components on these cells are rare.
Of the various aspects of modulation of immune cell func-
tions by surfactant components, the important findings
relevant to asthma are summarized in the following
section and illustrated in Fig. 1.
Allergen binding and allergen presentation
A very early step in the induction of allergic inflammation
is allergen uptake by dendritic cells, antigen processing
and subsequent antigen presentation to T lymphocytes.
SP-A has been shown to bind to pollen grains [32]. In
addition, it has been demonstrated that both SP-A and
SP-D interact with mite allergens in a carbohydrate-spe-
cific and calcium-dependent manner [33]. Moreover, SP-
A and SP-D were found to inhibit allergen-specific IgE
binding to the mite allergens. These data may suggest
that lung collectins inhibit the induction of allergic reac-
tions by direct allergen binding. This in turn would be
beneficial in preventing acute asthma attacks by inhibition
of the allergen-specific IgE binding and possibly also by
inhibition of allergen processing by dendritic cells.
However, further research is required to answer ques-
tions on possible interactions of dendritic cells with sur-
factant components.
Lymphocytes
T lymphocyte proliferation and cytokine release is an
important step in the further activation of the adaptive
immune system in asthma. This T-cell response can
induce B lymphocyte differentiation into specific IgE anti-
body secreting plasma cells. In addition, interleukin (IL)-5
release by T lymphocytes attracts and activates
eosinophils and prolongs eosinophil survival. Lympho-
cyte activity and proliferation can be downregulated by
surfactant phospholipids and by the lung collectins SP-A
and SP-D [34–37]. Both SP-A and SP-D inhibited pro-
duction and release of IL-2 [36,37]. Importantly, it has
recently been demonstrated that SP-A and SP-D inhibit
allergen-induced proliferation of lymphocytes and hista-
mine release from whole blood in response to the house
dust mite allergen Dermatophagoides pteronyssinus in a
dose-dependent manner [33,38]. These data suggest
that lung collectins may be important molecules in
asthma pathogenesis, both during the acute asthma
attack characterized by histamine release and in the
chronic airway inflammation by modulating lymphocyte
proliferation.
Available online http://respiratory-research.com/content/3/1/4Eosinophils
Eosinophils play an important role in chronic airway inflam-
mation in asthma. It has been shown by Cheng and co-
workers [39] that SP-A suppresses the production and
release of IL-8 by eosinophils stimulated by ionomycin.
The SP-A effect was concentration dependent and
reversed by addition of an anti-SP-A antibody. We
recently demonstrated that the IL-5 stimulated expression
of activation markers CD69 and HLA-DR on eosinophils
was reduced in the presence of natural bovine lipid extract
surfactant in a concentration-dependent fashion [40]. This
effect was presumably mediated by the lipid fraction of the
surfactant preparation and definitely not mediated by SP-
A, as the lipid-extracted surfactant contained no
hydrophilic surfactant proteins. One report states that
zymosan-activated eosinophils stimulate phosphatidyl-
choline secretion in cultured type II pneumocytes [41].
These findings may suggest a feedback-loop between sur-
factant release and eosinophil activation. Much more
research is required, however, to better understand the
network between surfactant components and eosinophil
activation and cytokine release.
Surfactant alterations in asthma
Animal models
Surfactant changes in asthma have been investigated
using animal models and hitherto only a few human
studies. In a murine model of asthma, it has been
reported that guinea pigs, sensitized with ovalbumin, and
then challenged with aerosolized antigen, reacted with a
leakage of plasma proteins into the airways, a markedly
increased airway resistance and an altered surfactant
performance, indicating a dysfunction [42]. It has also
been shown that prophylactic treatment of sensitized
animals with intratracheal instillation of surfactant reduces
the deteriorating lung function that would otherwise have
developed [43]. In studies at another laboratory, it was
demonstrated that treatment of immunized guinea pigs
with aerosolized surfactant alleviates an increase in
airway resistance [44].
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Figure 1
Interaction of surfactant with airway inflammation in asthma. After uptake through the airway surfactant barrier (right side of figure), allergens are
presented by dendritic cells (DC) to T cells (T) that release IL-2, proliferate, and differentiate into T helper 2 lymphocytes (Th2). These Th2 cells
release cytokines (IL-4 and IL-5) that attract eosinophils (Eos) and stimulate IgE production by differentiated B lymphocytes (B). IgE is bound to
mast cells (MC) that, upon stimulation with allergen, release mediators (such as histamine) inducing acute asthma attacks. Activated eosinophils
degranulate and release toxic mediators like eosinophil cationic protein (ECP), leukotrienes (LT), and transforming growth factor-β (TGF-β) that
induce epithelial damage and chronic airway inflammation. ECP is shown in bold because ECP, but not LT or TGF-β, has been shown to cause
surfactant dysfunction (unpublished data). The various effects of surfactant proteins SP-A, SP-B, SP-C and SP-D are indicated. SP-A and SP-D
are shown in bold to emphasize the importance of these surfactant molecules as immunomodulators in asthma. Mechanisms of stimulation,
activation, induction, or release are symbolized by arrows whereas inhibition, decrease, or down-regulation are symbolized by lines terminated by =.
? is used to indicate that the effects of SP-A/SP-D are presently unclear. PL = phospholipid.Human studies
In the past few years, data from patients with asthma have
accumulated, but are still rare. Kurashima et al. [45]
reported that sputum samples from patients with asthma
have a low surface activity. We have recently investigated
the inflammatory changes of BALF and the performance of
BALF surfactant in healthy controls and patients with mild
allergic asthma, before and after segmental allergen chal-
lenge [46]. Allergen challenge of asthmatics, but not of
healthy volunteers, significantly increased eosinophils, pro-
teins, the ratio of small to large surfactant aggregates
(SA/LA), and decreased surface activity measured with
the pulsating bubble surfactometer and the capillary sur-
factometer [46]. Analysis of phospholipid molecular
species from BALF and plasma suggested that changes in
phosphatidylcholine composition in BALF in asthmatic
subjects after allergen challenge was due to infiltration of
plasma lipoproteins, but not to phospholipid catabolism
[47]. Thus, the most likely reason for disturbed surfactant
function was that proteins had invaded the airways as they
reached a 10-fold increase in concentration. Proteins have
extensively been proven to inhibit surfactant function
[48,49]. Interestingly, a washing procedure with saline that
removed water-soluble inhibitors, such as the proteins,
restored surfactant function.
Lessons learned from comparative biology
There is a wide variety of lung structure and function
among vertebrates. Surfactant lipids and specific proteins
line the internal surface of the lung of all vertebrates.
While mammalian surfactant needs to provide low surface
tensions for alveolar stability and a reduction in the work of
breathing, surfactant in non-mammals has a more primitive
function with lower surface activity because larger respira-
tory units are more compliant and the risk of end-expiratory
collapse is far less. Here, surfactant appears to act as an
anti-glue that prevents surface adhesion in the case of
lung collapse, for example, during diving [50]. In contrast
to the saccular or alveolar structure of those lungs, the
respiratory tract of birds has a completely different struc-
ture. Birds have tubular lungs that do not contain alveoli.
Avian surfactant should, therefore, function predominantly
to maintain airflow through the lung tubules rather than
preventing alveolar collapse. From that, an interesting
approach to studying airway surfactant function and com-
position arises that could further elucidate the role of sur-
factant in the airways. This is all the more important as it
has been impossible so far to selectively sample airway
surfactant from mammalian lungs without substantial cont-
amination from the alveoli.
Consequently, we have recently investigated functional,
structural and biochemical parameters of avian surfactant.
While a uniform surfactant layer within the air tubules was
demonstrable by electron microscopy, tubular myelin was
absent in avian surfactant preparations. Although dynamic
surface properties were impaired in bird surfactant, the
ability to keep capillaries open was as good as with mam-
malian surfactant [51]. Compared to mammalian surfactant,
bird surfactant from duck and chicken was enriched in
DPPC, but contained less palmitoylmyristoyl-phosphatidyl-
choline (PC16:0/14:0) and palmitoylpamitoleoyl-phos-
phatidylcholine (PC16:0/16:1). For these last two
phosphatidylcholine species, no defined role in mammalian
surfactant has been established, but it has been shown
that their concentrations increase during fetal development
[52]. This might indicate a specific function within the alve-
olus, such as promoting adsorption of DPPC, which could
serve to open, or re-open, collapsed alveoli. While SP-B
was detectable in avian surfactant, both SP-A and SP-C
were absent. SP-B promotes film formation at the air–liquid
interface [53]. Consequently, its presence in bird surfac-
tant is consistent with good adsorption function demon-
strated by studies with the pulsating bubble surfactometer
and the capillary surfactometer. The importance of SP-B
for airway surfactant function is further supported by the
finding that heterozygous SP-B-deficient mice have higher
residual volumes than wild-type mice, a common pulmonary
function abnormality in obstructive airway disease [54]. An
interesting observation was that although avian surfactant
showed impaired functional properties under dynamic
cycling conditions with the pulsating bubble surfactometer,
it was sufficient to keep open tubules as studied with the
capillary surfactometer [51].
These data suggest that airway surfactant does not require
all the components found in alveolar surfactant prepara-
tions to achieve optimal function in the airway compart-
ment. This might explain why local differences in the
airways with regard to surfactant protein expression do not
necessarily account for dysfunctioning surfactant accord-
ing to the needs of the airway compartment. From an evolu-
tionary standpoint, it might have been more important to
express the hydrophilic surfactant proteins SP-A and SP-D
to optimize for allergen binding and innate immunity in the
airways rather than perfect surface properties.
Lessons learned from gene-targeted animal
models
An increasing body of evidence from studies with surfac-
tant protein deficient animals indicates that alterations in
the level of surfactant proteins contribute to the pathogen-
esis of a variety of lung diseases. Experiments with mice
deficient in the lung collectins SP-A and SP-D suggest
that altered levels or activities of the lung collectins in vivo
are associated with an increased risk of lung infections
[55]. Although both surfactant proteins have been shown
to bind allergens or to modify the production and release
of inflammatory mediators by allergic effector cells in vitro,
in vivo data in SP-A or SP-D-deficient mice to rule out
their role in allergic inflammation are missing to date.
While SP-A-deficient mice have no apparent abnormalities
Available online http://respiratory-research.com/content/3/1/4
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enlargement of terminal airways and emphysema [57].
Signs of obstructive airway disease in SP-D knock-out
mice, however, probably reflect the result of an imbal-
anced chronic lung inflammation with pathological airway
remodeling rather than an impact of a lack of SP-D on bio-
physical surfactant function in the airways.
Hydrophobic SP-B and SP-C are very important for the
biophysical surfactant properties. With regard to in vivo
lung function, SP-B is the most important surfactant
protein. Infants bearing mutations of the SP-B gene that
lead to an absence of SP-B and gene-targeted mice
lacking SP-B die from respiratory failure after birth
[58,59]. In heterozygous SP-B-deficient mice (which have
a 50% decrease in SP-B mRNA and SP-B protein com-
pared to wild type), lung compliance decreases and resid-
ual volumes increase [54]. The latter finding suggests air
trapping, indicating that airway obstruction might have
been due to a surfactant dysfunction caused by the SP-B
deficiency. An interesting finding results from mice overex-
pressing IL-4 in the airways under the control of the Clara
cell secretory protein promoter. While total SP-A and SP-
B levels in bronchoalveolar fluids and lung homogenates
were increased, surfactant protein B positive cells were
decreased in bronchial and bronchiolar epithelial cells, but
staining was unchanged in alveolar type II cells [60]. It
might be speculated that in asthma, the allergic inflamma-
tion with increased amounts of IL-4 in the airway environ-
ment leads to diminished local SP-B levels that can
account for airway obstruction as seen in heterozygous
SP-B-deficient mice.
In contrast to the unequivocal relevance of SP-B for in
vivo lung function, SP-C-deficient mice develop normally
and they do not show alterations in the histopathology of
airways or alveoli [61]. Impaired pulmonary function
showing decreased hysteresivity without significant
changes in airway and tissue resistance, however, sug-
gests that SP-C may stabilize alveolar surfactant films at
low lung volumes. In a murine asthma model, it has
recently been demonstrated that allergen-induced airway
inflammation is associated with downregulation of SP-C,
whereas SP-A and SP-D are upregulated [62]. The down-
regulation of the human SP-C promoter in this animal
model was found to be IL-5 dependent, highlighting a
potential role for eosinophilic inflammation as eosinophils
produce and respond to IL-5. SP-C levels in patients with
asthma need to be determined.
Clinical aspects and therapeutic implications
Although there is no direct proof that surfactant dysfunc-
tion in human asthma causes airway obstruction, the
above-mentioned and published data from the literature
support the concept that poor functioning surfactant con-
tributes to the pathophysiological scenario in asthma. Thus,
it seems justified to investigate the potential role of surfac-
tant therapy in asthma. There are two different ways to
improve the surfactant balance in the airways. Firstly,
various drugs that are commonly used in asthma therapy,
like corticosteroids, β-adrenergic agents and theophylline
have been shown to stimulate surfactant synthesis or
secretion [63–65]. It remains to be determined, however,
whether pharmacological stimuli can augment surfactant
secretion to an extent that could be clinically relevant. Sec-
ondly, treatment with exogenous surfactant has been
shown to improve allergic airway obstruction in animal
models of asthma [43,44]. Human data are rare; a small
randomized controlled trial demonstrated a significant
improvement in pulmonary function data after inhalation of
surfactant in patients with acute asthma attacks [66]. In
contrast, nebulized surfactant did not alter airway obstruc-
tion and bronchial responsiveness to histamine in asth-
matic children with mild airflow limitation [67]. A
prospective randomized controlled trial of aerosolized syn-
thetic surfactant (Exosurf) in 87 adult patients with stable
chronic bronchitis revealed a significant improvement of
11% in forced expiratory volume in 1 s, a 6% decrease in
thoracic gas trapping, and an improvement of sputum
transportability [68]. Recently, it has been reported that
exogenous surfactant improved disease course in infants
with respiratory syncytial virus bronchiolitis [69], an
obstructive airway disease for which a surfactant dysfunc-
tion has been demonstrated [70]. Altogether, these results
demonstrate that exogenous surfactant therapy might have
at least some beneficial effect in patients with asthma and
obstructive airway disease. Exogenous surfactant therapy
is expensive, however, and thus still limited to research and
case studies. Future investigations will help to unravel rele-
vant surfactant components with the best anti-obstructive
effects and the most potent anti-inflammatory capacity.
Conclusions
Pulmonary surfactant with an optimal function in the
airways is important because it stabilizes the conducting
airways, prevents fluid accumulation within the airway
lumen, improves bronchial clearance, acts as a barrier
against the uptake of inhaled agents and has important
immunomodulatory properties. In asthma, it has been
demonstrated that there is a surfactant dysfunction mainly
due to inhibition by proteins that enter the airways during
the inflammatory process. Surfactant dysfunction in
asthma adds to our understanding of the pathophysiologi-
cal scenario of airway obstruction in this respiratory
disease. Therapeutic interventions that improve airway sur-
factant balance by stimulating the endogenous surfactant
system or by exogenous surfactant supplementation might
be of potential benefit in reversing airway obstruction and
in modulating the allergic inflammation in asthma. To
succeed in finding safe and effective ways of manipulating
airway inflammation and airway obstruction by surfactant
components may prove helpful in asthma.
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